Biologics firm Bioventus has appointed Alessandra Pavesio to become the company’s new chief science officer.

Bioventus focuses on orthopedic healing technologies. Pavesio will will lead various functional areas for the Durham company including research, product development, clinical affairs, clinical development, project management and regulatory affairs. She comes to Bioventus from the Boston University Coulter Translational Partnership, a foundation-sponsored research program designed to enhance clinical impact and wealth creation through the development and transfer of innovative intellectual properties from university laboratories to commercial practice.

Pavesio has held executive R&D positions at two biomedical companies, Anika Therapeutics Massachusetts company that manufactures and markets products based on hyaluronic acid, and Fidia Advanced Biopolymers, a European firm acquired by Anika that specialized in hyaluronic acid-based regenerative medicine products for use in bio-orthopedics, wound healing and specialty surgery. Her 20-year career includes experience developing – from concept to bedside – more than 25 Class-III innovative medical devices/biologics, designed for regeneration of soft and hard tissues, that have been licensed to companies worldwide.

Pavesio, who will be based at Bioventus’ Durham headquarters, starts on Aug. 5. She will report to Bioventus CEO Mark Augusti.